Maria Bonaria Uccheddu
Research Subjects
Research Interests
Maria Bonaria Uccheddu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Anouska Jha
1 shared publicationCamille Chassat
1 shared publicationCharlotte Carpenter
1 shared publicationCharlotte Gary
1 shared publicationDaisy Bridge
1 shared publicationDiana Sufragiu
1 shared publication
Latest Publications
- 9 November 2026
- Published by Springer Nature in Nature Reviews Neurology
- p. 1
Hormonal changes must be part of the conversation in neurological care
- 9 November 2026
- Published by Springer Nature in Nature Reviews Neurology
- p. 1
Hormonal changes must be part of the conversation in neurological care
- Open Access
- 22 August 2026
- Published by Springer Nature in BMC Neurology
Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravis
Background: Patients with generalised myasthenia gravis (gMG) can experience remaining symptoms despite treatment. Our study aimed to describe how remaining symptoms and their fluctuations may affect a person’s daily life while living with gMG. Methods: A modified-Delphi panel (two survey rounds) was conducted with adult patients with gMG ( n =20) from seven European countries (France, Germany, Italy, the Netherlands, Sweden, Switzerland, and the UK). A scientific advisory committee including two neurologists and three patient advocacy group representatives guided the study. Consensus was defined as ≥80% participants in agreement (rated 7‒9 on a 9-point Likert scale) on a particular statement. Results: Participants receiving a range of gMG treatments highlighted the personal and variable impacts of remaining symptoms in five key domains: daily activities, social life, mental wellbeing, work and education, and future plans. Across all domains, >40% of participants declared a high impact (rating 7–9 on Likert scale), with the highest proportion of patients declaring a high impact in the mental wellbeing domain (63%). Adjustments to daily activities, evening plans, working hours or even career moves, were frequently noted impacts of remaining symptoms and fluctuations. Participants also mentioned loss of independence and fears about forthcoming symptom severity as impactful. One statement reached consensus in agreement: “if my symptoms were better controlled, I would have greater freedom to do the things I enjoy and lead a more satisfying life”. Conclusions: This study is the first to investigate the specific impacts of remaining symptoms of gMG on patients’ daily lives and how fluctuations may contribute to this impact. These results demonstrate the burden of these remaining symptoms for patients, suggesting that more effective therapeutic strategies leading to more sustained disease control would likely improve patients’ daily lives.
- 22 August 2026
- Published by Springer Nature in BMC Neurology
Open AccessPatient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravis
Background: Patients with generalised myasthenia gravis (gMG) can experience remaining symptoms despite treatment. Our study aimed to describe how remaining symptoms and their fluctuations may affect a person’s daily life while living with gMG. Methods: A modified-Delphi panel (two survey rounds) was conducted with adult patients with gMG ( n =20) from seven European countries (France, Germany, Italy, the Netherlands, Sweden, Switzerland, and the UK). A scientific advisory committee including two neurologists and three patient advocacy group representatives guided the study. Consensus was defined as ≥80% participants in agreement (rated 7‒9 on a 9-point Likert scale) on a particular statement. Results: Participants receiving a range of gMG treatments highlighted the personal and variable impacts of remaining symptoms in five key domains: daily activities, social life, mental wellbeing, work and education, and future plans. Across all domains, >40% of participants declared a high impact (rating 7–9 on Likert scale), with the highest proportion of patients declaring a high impact in the mental wellbeing domain (63%). Adjustments to daily activities, evening plans, working hours or even career moves, were frequently noted impacts of remaining symptoms and fluctuations. Participants also mentioned loss of independence and fears about forthcoming symptom severity as impactful. One statement reached consensus in agreement: “if my symptoms were better controlled, I would have greater freedom to do the things I enjoy and lead a more satisfying life”. Conclusions: This study is the first to investigate the specific impacts of remaining symptoms of gMG on patients’ daily lives and how fluctuations may contribute to this impact. These results demonstrate the burden of these remaining symptoms for patients, suggesting that more effective therapeutic strategies leading to more sustained disease control would likely improve patients’ daily lives.
- 7 January 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (3) , 159-170
Inclusion in neurological research: empowering people living with neurological diseases
The value of involving people living with diseases in the research process is increasingly recognized by professional associations and regulatory agencies alike. Patient contributions range from disease prevention and diagnosis to medication planning, and from advocacy to guideline production and clinical trial design. Thanks to the efforts of activists and advocates, new models of patient inclusion in medical research are being developed to replace outdated non-participative and tokenistic paradigms. New modalities of patient participation in research — for example, the introduction of patient experts, who work closely with researchers and clinicians — have progressively empowered individuals who are living with diseases. In this Perspective, we provide an overview of the current status of patient involvement in medical research, with a specific focus on neurology. We also discuss the existing and future roles of patient experts in neurological research.
- 7 January 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (3) , 159-170
Inclusion in neurological research: empowering people living with neurological diseases
The value of involving people living with diseases in the research process is increasingly recognized by professional associations and regulatory agencies alike. Patient contributions range from disease prevention and diagnosis to medication planning, and from advocacy to guideline production and clinical trial design. Thanks to the efforts of activists and advocates, new models of patient inclusion in medical research are being developed to replace outdated non-participative and tokenistic paradigms. New modalities of patient participation in research — for example, the introduction of patient experts, who work closely with researchers and clinicians — have progressively empowered individuals who are living with diseases. In this Perspective, we provide an overview of the current status of patient involvement in medical research, with a specific focus on neurology. We also discuss the existing and future roles of patient experts in neurological research.